Toxicities and outcomes among septuagenarians and octogenarians with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone therapy

References

• Muller AM, Ihorst G, Mertelsmann R. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1–12.
   PubMed Web of Science ®Google Scholar
• Devesa SS, Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992;52(19 Suppl.): 5432s–5440s.
   PubMed Web of Science ®Google Scholar
• Fisher RI, . Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993;328:1002–1006.
   PubMed Web of Science ®Google Scholar
• Gordon LI, . Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992;327:1342–1349.
   PubMed Web of Science ®Google Scholar
• Coiffier B, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar
• Feugier P, . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005;23:4117–4126.
   PubMed Web of Science ®Google Scholar
• Fisher RI, Miller T, O'Connor OA. Diffuse aggressive lymphoma. Hematology Am Soc Hematol Educ Program 2004:221–236.
   PubMedGoogle Scholar
• Lyman GH, . Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302–4311.
   PubMed Web of Science ®Google Scholar
• Dodos F, . Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol 2008;97:318–326.
   PubMed Web of Science ®Google Scholar
• Limat S, . Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Ann Oncol 2003;14:277–281.
   PubMed Web of Science ®Google Scholar
• Gomez H, . Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16:2352–2358.
   PubMed Web of Science ®Google Scholar
• Lyman GH, . Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapy. Leuk Lymphoma 2003;44:2069–2076.
   PubMed Web of Science ®Google Scholar
• Bertini M, Boccomini C, Calvi R. The influence of advanced age on the treatment and prognosis of diffuse large-cell lymphoma (DLCL). Clin Lymphoma 2001;1:278–284.
   PubMedGoogle Scholar
• Pfreundschuh M, . Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105–116.
   PubMed Web of Science ®Google Scholar
• Mey UJ, . Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. Support Care Cancer 2007;15:877–884.
   PubMed Web of Science ®Google Scholar
• Case DC Jr, . Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients. Clin Lymphoma Myeloma 2007;7:354–360.
   PubMedGoogle Scholar
• Lee KW, . Doxorubicin-based chemotherapy for diffuse large B-cell lymphoma in elderly patients: comparison of treatment outcomes between young and elderly patients and the significance of doxorubicin dosage. Cancer 2003;98:2651–2656.
   PubMed Web of Science ®Google Scholar
• Grann VR, . Outcomes and diffusion of doxorubicin-based chemotherapy among elderly patients with aggressive non-Hodgkin lymphoma. Cancer 2006;107:1530–1541.
   PubMed Web of Science ®Google Scholar
• Link BK, . Diffuse large B-cell lymphoma in the elderly: diffusion of treatment with rituximab and survival advances with and without anthracyclines. Leuk Lymphoma 2011;52:994–1002.
   PubMed Web of Science ®Google Scholar
• Hasselblom S, Stensomn M, Werlenius O, . Improved outcome for very elderly patients with diffuse large B-cell lymphoma in the immunochemotherapy era. Leuk Lymphoma 2011 Oct 10. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Bosly A, . Achievement of optimal average relative dose intensity and correlation with survival in diffuse large B-cell lymphoma patients treated with CHO. Ann Hematol 2008;87:277–283.
   PubMed Web of Science ®Google Scholar
• Pettengell R, Schwenkglenks M, Bosly A. Association of reduced relative dose intensity and survival in lymphoma patients receiving CHOP-21 chemotherapy. Ann Hematol 2008;87:429–430.
   PubMed Web of Science ®Google Scholar
• Hirakawa T, . Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 2010;89:897–904.
   PubMed Web of Science ®Google Scholar
• Terada Y, Nakamae H, Aimoto R, . Impact of relative dose intensity (RDI) in chop combined with rituximab (R-CHOP) on survival in diffuse large B-cell lymphoma. J Exp Clin Cancer Res 2009; 28:116.
   PubMed Web of Science ®Google Scholar
• Rodriguez J, McLaughlin P, Hagemeister FB, . Follicular large cell lymphoma: an aggressive lymphoma that often presents with favorable prognostic features. Blood 1999;93:2202–2207.
   PubMed Web of Science ®Google Scholar
• Ganti AK, Weisenburger DD, Smith LM, . Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline-based chemotherapy: the Nebraska lymphoma study group experience. Ann Oncol 2006;17:920–927.
   PubMed Web of Science ®Google Scholar
• Miller MD, . Rating chronic medical illness burden in geropsychiatric practice and research: application of the Cumulative Illness Rating Scale. Psychiatry Res 1992;41:237–248.
   PubMed Web of Science ®Google Scholar
• Hudon C, Fortin M, Soubhi H. Abbreviated guidelines for scoring the Cumulative Illness Rating Scale (CIRS) in family practice. J Clin Epidemiol 2007;60:212.
   PubMed Web of Science ®Google Scholar
• Salvi F, . A manual of guidelines to score the modified cumulative illness rating scale and its validation in acute hospitalized elderly patients. J Am Geriatr Soc 2008;56:1926–1931.
   PubMed Web of Science ®Google Scholar
• Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990;8:1935–1937.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE) and Common Toxicity Criteria (CTC), V3. Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
   Google Scholar
• Pfistner B, . International harmonization of trial parameters in malignant lymphoma. Eur J Haematol Suppl 2005;(66):53–54.
   PubMedGoogle Scholar
• Cheson BD, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Ancestry.com. Social Security Death Index [database on-line]. Provo, UT: Ancestry.com Operations Inc.; 2010.
   Google Scholar
• Meguro A, . Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2012;53:43–49.
   PubMed Web of Science ®Google Scholar
• Harris PA, . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009;42: 377–381.
   PubMed Web of Science ®Google Scholar
• Juweid ME, . Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography. J Clin Oncol 2005;23:4652–4661.
   PubMed Web of Science ®Google Scholar
• Musolino A, . Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 2011;117:964–973.
   PubMed Web of Science ®Google Scholar
• Wilson WH, . Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol 2008;26:2717–2724.
   PubMed Web of Science ®Google Scholar
• Peyrade F, . Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011;12:460–468.
   PubMed Web of Science ®Google Scholar